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Objectives: Measurement of the incidence of the human immunodeficiency virus
(HIV) is very important for epidemiological studies. Here, we determined the
recency period with the AxSYM avidity assay and the BED-capture enzyme
immunoassay (BED-CEIA) in Korean seroconverters.
Methods: Two hundred longitudinal specimens from 81 seroconverters with
incident HIV infections that had been collected at the Korea National Institute of
Health were subjected to the AxSYM avidity assay (cutoff Z 0.8) and BED-CEIA
(cutoff Z 0.8). The statistical method used to estimate the recency period in
recent HIV infections was nonparametric survival analyses. Sensitivity and
specificity were calculated for 10-day increments from 120 days to 230 days to
determine the recency period.
Results: The mean recency period of the avidity assay and BED-CEIA using a
survival method was 158 days [95% confidence interval (CI), 135e181 days] and
189 days (95% CI, 170e208 days), respectively. Based on the use of sensitivity and
specificity, the mean recency period for the avidity assay and BED-CEIA was 150
days and 200 days, respectively.
Conclusion: We determined the recency period to estimate HIV incidence in
Korea. These data showed that the nonparametric survival analysis often led to
shorter recencyperiods thananalysis of sensitivity and specificity as a newmethod.
These findings suggest that more data from seroconverters and other methodolo-
gies are needed to determine the recency period for estimating HIV incidence.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
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Measurement of the incidence of the human immu-
nodeficiency virus (HIV) is very important for epide-
miological studies because it can provide basic data for:
(1) determining which medication to use, (2) detecting
changes in patterns of HIV infection, and (3) evaluating
the effects of education programs on HIV prevention in
vulnerable groups. However, the traditional method of
estimating incidence by following longitudinal cohorts
is time-consuming and expensive.
As a result, for some time, several attempts have been
made to calculate HIV incidence using cross-sectional
studies [1]. The United States Centers for Disease
Control and Prevention (CDC) conducts laboratory-
based surveillance on HIV incidence on a national
level by developing diagnostic kits for identifying recent
infections and using a formula to estimate HIV inci-
dence with data collected from its Serologic Testing
Algorithm for Recent HIV Seroconversion project [2].
After a person is infected with HIV, a certain amount
of time must pass before a threshold amount of antibody
is produced. That time interval is called the recency
period and is considered to be a key variable for esti-
mation of HIV incidence [3]. Recency periods vary
among individuals and by race, so a study to estimate
the recency period should be conducted first to accu-
rately measure HIV incidence in the Korean population
[4].
The recency period, for the purpose of a particular
test, is the mean time interval between the estimated
time of HIV infection and an arbitrary time at which the
given threshold of the assay is attained. In the current
study, we estimated the mean recency period to deter-
mine HIV incidence in Korea using longitudinal data
and specimens from seroconverters whose time of HIV
infection could be estimated reliably.2. Materials and methods
2.1. Specimens
We looked at HIV seroconverters who were desig-
nated as “indeterminate” in the initial HIV antibody
test, but who later converted to being “positive” in the
repeat test among HIV-infected individuals detected
from 2005 to 2012. Among them, 81 individuals with at
least two specimensdclassified as “indeterminate
specimens” prior to the confirmation of HIV infection
and the confirmatory positive specimendwere finally
selected. We also included their specimens, which were
collected for immunoassay prior to treatment after they
were confirmed to be HIV-positive. A total of 200
specimens from these 81 individuals were used. The
largest number of specimens from a single individual
was four and the mean number of specimens per indi-
vidual was 2.5.2.2. Collection of specimens from HIV
seroconverters
In South Korea, if a sample is HIV-positive in a
screening laboratory, the sample is referred to the
Institute for Health and the Environment (IHE) for
confirmatory testing. For samples for which the IHE
cannot make a definitive diagnosis, a designation of
“indeterminate” is assigned, and the sample sent to the
Division of AIDS of the Korea National Institute of
Health (KNIH) for testing. If the KNIH test result
remains “indeterminate”, a notification is made to the
screening laboratory to instruct it to collect another
blood sample after a certain period of time, and to send
it to the KNIH. The notified laboratory sends the next
blood sample directly to the KNIH for retesting [5].
Through such processes, the KNIH identified
HIV seroconverters and collected their data and
specimens.
2.3. Test methods
Two assays were used in the current study to esti-
mate recency periods: AxSYM avidity assay and BED-
capture enzyme immunoassay (BED-CEIA). The
avidity assay is designed to measure antibody avidity
using a modified fourth-generation enzyme-linked
immunosorbent assay (ELISA). When a reactive
specimen is treated with 1.5 M guanidine, hydrogen
bonds are destroyed, which inhibits secondary re-
actions [6]. The specimens were assayed by automated
AxSYM HIV Ag/Ab Combo (Abbott Diagnostics Di-
vision, Wiesbaden, Germany). We defined avidity to
be the ratio of the strength of antigeneantibody
(AgeAb) binding in specimens treated with guanidine
to that in specimens not treated with guanidine [6,7].
For the BED-CEIA, normalized optical density (OD-n)
for each specimen was calculated based on the prin-
ciple that HIV-specific immunoglobulin (Ig)G can be
detected by a plate coated with goat-antihuman-IgG
and the BED-Biotin peptide gp41 [8]. The stated
cutoff value in the kit insert of the commercially
available BED-CEIA was 0.8. The cutoff value for the
avidity assay was set at 0.8 in a study conducted to
develop avidity assays for HIV-infected persons in
Korea [9].
2.4. Determination of the recency period
The term recency period was used in the
current study to refer to the time span between HIV
infection and a specified assay cutoff. A total of 200
specimens from 81 persons with incident HIV in-
fections were tested by the avidity assay and BED-
CEIA. In both assays, we estimated the expected time
for the OD-n level in HIV-positive individuals to reach
the 0.8 cutoff. All analyses were done using the
SAS software (version 9.3; SAS Institute, Inc., Cary,
NC).
Table 1. Characteristics of HIV seroconverters (NZ 81)
in South Korea.a
Number of persons (%)
Sex
Male 77 (95.1)
Female 4 (4.9)
Age (y)
<20 4 (4.9)
20e29 26 (32.1)
30e39 21 (25.9)
40e49 15 (18.5)
50 14 (17.3)
Unknown 1 (1.2)
Year
2005e2006 15 (18.5)
2007e2008 17 (21.0)
2009e2010 23 (28.4)
2011e2012 26 (32.1)
Stage
Eclipse phase (10 d) e
I (17 d) 2 (2.5)
II (22 d) 33 (40.7)
III (25 d) 6 (7.4)
IV (31 d) 38 (46.9)
V (101 d) 2 (2.5)
VI (open-ended) e
Initial CD4þcell countb
< 200 8 (16.7)
200e349 13 (27.1)
350e499 17 (35.4)
500 11 (22.9)
aAge denotes the age at the time of diagnosis ofHIV infection; Year denotes
the year of confirmation of HIV diagnosis; and CD4þ cell counts denotes
the data from immunoassay results undertaken <6 mo after HIV-positive
confirmation test; bThese percentages were calculated after excluding
samples with missing values.
HIV Z human immunodeficiency virus.
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statistical method
The KaplaneMeier method [10] was applied to the
results of the avidity assay and BED-CEIA. We used a
cutoff value of 0.8 for the avidity assay and BED-CEIA
for censoring in the KaplaneMeier analysis. A nonpara-
metric method was used because it was assumed that
recency periods do not form a normal distribution. The
cumulative probability that the test results would be lower
than the cutoff value for a certain period of time was
calculated to estimate the mean recency period. This co-
incides with the time when the test value will surpass the
cutoff value. For each of the 81 patients, the date of first
collection of the blood specimen was referred to as “time
since HIV infection” (“HIV infection period”). Based on
the patterns of the AgeAb response found in the test re-
sults of the first specimen, patients were categorized into
one of six laboratory stages of primary HIV infection
[11,12]. According to the Fiebig classification, the period
of HIV infection is divided into seven stages based on the
emergence of viral markers such as HIV RNA, ELISA
antigen, ELISA antibody, and Western blot. That is:
eclipse phase (10 days), stage I (17 days), stage II (22
days), stage III (25 days), stage IV (31 days), stage V (101
days), and stage VI (open-ended).
2.6. Estimation of the recency period using
sensitivity and specificity
Specimens with results of the avidity assay and
BED-CEIA of 0.8 (cutoff) were regarded to be recent
infections.With 10-day periods between 120 days and 230
days since the first HIV-positive test, we distinguished
recent infection from long-standing infection. From the
data, sensitivity and specificitywere calculated to estimate
the recency period. Sensitivity was defined as the pro-
portion of specimens at or below the threshold day for
recent infection among specimens classified as recent in-
fections by new assays looking at incidence. Specificity
was defined as the proportion of specimens above the
threshold day for recent infection among specimens clas-
sified as long-standing infections by new assays looking at
incidence.We took into account sensitivity and specificity
to make an optimal estimation of the recency period.3. Results
3.1. Test results
Some of the basic information about the 81 patients
(sex; age at the time of diagnosis of HIV infection; year
of confirmation of HIV diagnosis; stages of infection) is
shown in Table 1. Ninety-seven percent of the patients
were male. For most of the patients, infection was
detected when they were aged in their 20s (31%) or 30s
(28%). Twenty-six individuals (32%) were identified
between 2011 and 2012, whereas 23 individuals (28%)
were reported between 2009 and 2010. The number ofpatients in stage II (22 days after infection) at the time of
the first positive test was 33 (41%). The number of
patients in stage IV (31 days after infection) was 38
(47%). Except for two patients, 79 (98%) were esti-
mated to be in the 1st month of HIV infection. In 49
individuals, immunoassays performed within 6 months
after HIV-positive test showed a CD4þ cell count of
<200 in 16.7% of the cases and 350e499 in 35.4% of
the cases and the mean CD4þ cell count was 369. The
mean results of the avidity assay and BED-CEIA of
indeterminate specimens were 0.311 and 0.065,
respectively. The mean tracking duration for individuals
was 92 days (data not shown).
3.2. Estimation of the recency period
3.2.1. Estimation of the recency period using
survival analyses
Figure 1 shows how the results of the avidity assay
and BED-CEIA changed in each of the 81 test patients
in relation to time since HIV infection. The avidity assay
was carried out on 191 specimens from 79 patients after
Figure 1. Distribution in results of the AxSYM avidity index and BED-capture enzyme immunoassay by human immunodefi-
ciency virus seroconverters.
190 H.-K. Yu, et alexcluding two patients with only one longitudinal
observation each. All 200 specimens from 81 patients
were tested with the BED-CEIA. Table 2 contains the
results of KaplaneMeier analyses undertaken on each
set of assay results to estimate the recency period. The
recency period of the avidity assay was 158 days [95%
confidence interval (CI); 135e181 days]. The recency
period of the BED-CEIA was estimated to be 189 days
(95% CI; 170e208 days).
3.2.2. Estimation of the recency period using
sensitivity and specificity
We distinguished recent infection from long-standing
infection by rearranging recency periods into 10-dayintervals from 120 days to 230 days based on the calcu-
lation of the time interval between HIV infection and until
the cutoff value was reached (Table 3). Sensitivity and
specificity for individual recency periods are also shown in
Table 3. When sensitivity and specificity were considered
together and both values reached the highest values two
values, the recency periods in the avidity assay and in
BED-CEIA, were 150 days and 200 days, respectively.4. Discussion
In the current study, we estimated the recency period
by analyzing specimens from HIV seroconverters in the
Table 2. Mean recency period at the AxSYM avidity
assay and BED-capture enzyme immunoassay.
Assay Cutoff value
Mean recency
period (d) 95% CI
Avidity 0.8 158 135 181
BED-CEIA 0.8 189 170 208
CEIA Z capture enzyme immunoassay; CI Z confidence interval.
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period for the measurement of HIV incidence in Korea.
Assay results for new incidence were subjected to
KaplaneMeier analyses and to assessments using
sensitivity and specificity. The results of KaplaneMeier
analyses suggested that the recency periods of the
avidity assay and BED-CEIA were 158 days and 189
days, respectively. Based on the use of sensitivity and
specificity, the recency periods for the avidity assay and
BED-CEIA were 150 days and 200 days, respectively.
The recency period of the BED-CEIA (which is
currently in widespread use for the detection of early HIV
infection) is 155 days [8]. Recently, the US CDC added
new patients to predict the recency period of the BED-
CEIA, and estimated it to be 197 days, which is longer
than before. This was because of the inclusion of more
races and subtypes in the specimens, providing proof that
the recency period can differ depending on the character-
istics of test patients. Even in patients with the same sub-
type, recency periods change among different races [1].
Recency periods can also differ depending on the
assay used and the method of data analysis. The recency
period of a less sensitive assay is 129 days (95% CI,
109e149 days) [9] whereas that of the avidity assay is
141 days (95% CI, 119e160 days) [10]. The same
phenomenon was observed in the current study becauseTable 3. Use of different recency periods of the AxSYM
avidity assay and BED-capture enzyme immu-
noassay to identify recent human immunodefi-
ciency virus infections.
Recency
period (d)
Avidity assay BED-CEIA
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
120 82.0 86.2 79.5 80.8
130 86.5 75.9 84.8 76.9
140 91.0 69.0 88.9 69.2
150 92.5 69.0 90.1 65.4
160 93.2 58.6 92.4 65.4
170 95.5 55.2 94.2 61.5
180 96.2 55.2 94.7 57.7
190 97.0 51.7 96.5 57.7
200 97.7 51.7 97.7 57.7
210 97.7 48.3 97.7 53.8
220 97.7 44.8 98.2 50.0
230 98.5 44.8 98.8 50.0
CEIA Z capture enzyme immunoassay.the recency period of the BED-CEIA was longer than
that of the avidity assay. With regard to the method of
data analyses, the linear mixed effects (LME) regression
model generated a slightly longer recency period than
KaplaneMeier analyses [176 days (95% CI, 164e188
days) versus 162 days (95% CI, 152e172 days)], which
highlights the need to choose an appropriate analysis
method that fits data characteristics [1].
Given that recency periods can vary depending on
race, HIV subtype, the assay, and method of data ana-
lyses, calculating an optimal recency period that can
accommodate the characteristics of the test centers of a
given country is important. Thus, on the basis that the
patients are of Korean race and have subtype-B infection,
we calculated the mean recency period using two assays
and two methods of analyses. Considering the relatively
small number of seroconverter specimens available in
Korea and the shorter tracking period, we decided to
undertake KaplaneMeier analyses. In addition, sensi-
tivity and specificity were calculated for each recency
period after an assumption about recency periods was
made. In general, sensitivity and specificity are used to
determine the type of assay kit and cutoff value of the
test. Moreover, most of our data tended to show high
sensitivity and low specificity because of short infection
periods and, considering that the BED-CEIA produces
many false-positive results, we prioritized specificity
over sensitivity in determination of the recency period.
There was no significant difference between the
recency periods determined by survival analyses and by
sensitivity and specificity. The recency period of the
BED-CEIA at a cutoff value of 0.8 differed between 189
days (95% CI, 170e208 days) and 200 days depending
on the analysis methods used. In both cases, the recency
period was similar to the 197-day period set by the US
CDC upon consideration of more recent findings. Our
analyses regarding the estimation of recency period had
two advantages. First, in most cases, the estimated date
of HIV infection was taken to be the midpoint between
the last HIV-negative test and the first HIV-positive test
after tracking the test history of each individual. How-
ever, we estimated the date of HIV infection by looking
at the level of AgeAb response at the time of the first
HIV-positive test rather than studying the patient’s
test history and, thus, could reduce the error margin of
prediction significantly. Second, for estimation of
recency periods, we tried to use the analysis of sensi-
tivity and specificity as a new method.
The current study had three main limitations. First,
selection bias occurred in choosing 81 patients among
342 seroconverters detected in Korea until 2012. Also,
the number of test patients was small. Second, because of
the limited number of longitudinal observations per pa-
tient, we could not use the LME regression model, which
is a parametric method. Third, with 84% of specimens
concentrated in recency periods of 5 months, only a
small number of specimens could be classified as late
192 H.-K. Yu, et alinfections. This led to a lower specificity than sensitivity
because specificity was defined as the ability to correctly
detect longstanding HIV infections.
Despite these limitations, however, the current study
was important because it was the first attempt to deter-
mine the recency period in Korea and allowed for the
measurement of HIV incidence in this country.
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